Table 3.
Univariate analysis for the 3-outcome model of complete, partial response, and no response, to rituximab therapy. Values expressed as median (range) or proportion (%).
| Variable | Complete response (n = 17) | Partial response (n = 8) | No response (n = 14) | P value |
|---|---|---|---|---|
| Age at diagnosis (years) | 5 (1–33) | 7.5 (2–30) | 12 (1.9–40) | 0.12 |
| Age at transplant (years) | 13 (5–48) | 22.5 (8–41) | 30 (5.5–48) | 0.07 |
| Male gender | 14/17 (82.4) | 2/8 (25) | 6/14 (42.8) | 0.01 |
| Time to end stage renal disease (years) | 3 (0.16–19) | 3 (0.6–9) | 4 (0.5–12) | 0.65 |
| Time to relapse (days) | 1 (1–3513) | 8 (1–150) | 22 (1–828) | 0.12 |
| Deceased donor source | 11/17 (64.7) | 6/8 (75) | 10/14 (71.4) | 1.00 |
| Serum albumin at relapse (g/dL) | 2.7 (1.4–4.4) | 3.2 (2–4) | 2.3 (1.2–3.3) | 0.05 |
| Proteinuria (g/day) | 10.25 (1.1–97.4) | 5.8 (2–14) | 7.64 (2.4–20) | 0.19 |
| Plasmapheresis | 0.43 | |||
| <20 treatments | 7/17 (41.2) | 2/8 (25) | 6/14 (42.8) | |
| 21–50 treatments | 7/17 (41.2) | 3/8 (37.5) | 2/14 (14.4) | |
| >50 treatments | 3/17 (17.6) | 3/8 (37.5) | 6/14 (42.8) | |
| Pretransplant plasmapheresis | 6/17 (35.3) | 1/8 (12.5) | 2/14 (14.4) | 0.37 |
| Posttransplant plasmapheresis | 16/17 (94.1) | 8/8 (100) | 14/14 (100) | 1.00 |
| Rituximab doses | 2 (2–6) | 3 (1–5) | 4 (2–6) | 0.03 |
| Time from transplant to rituximab (days) | 120 (4–3543) | 343 (10–1095) | 276 (65–1050) | 0.08 |
| Time from relapse to rituximab (days) | 62 (3–927) | 271 (9–1086) | 179 (57–1048) | 0.03 |
| Diagnosis of PTLD | 2/17 (11.8) | 1/8 (12.5) | 0/14 (0) | 0.41 |
| Cyclophosphamide use | 1/17 (5.9) | 1/8 (12.5) | 2/14 (14.4) | 0.81 |
| Tacrolimus use | 13/17 (76.5) | 8/8 (100) | 9/14 (64.3) | 0.18 |
| Mycophenolate mofetil use | 16/17 (94.1) | 8/8 (100) | 13/14 (92.8) | 1.00 |